Abstract The recent JUPITER trial demonstrated that potent statin therapy reduces by 50 % the risk of heart attack and stroke among men and women with low levels of lowdensity lipoprotein (LDL)-cholesterol who are at increased vascular risk due to elevated levels of C-reactive protein (CRP), a biomarker of low-grade systemic inflammation. In JUPITER, both absolute risk and the absolute risk reduction with statin therapy were related to the level of CRP, whereas no such relationship was observed for LDL-C. Further, ontreatment levels of CRP and LDL-C were independently associated with residual risk, and the genetic determinants of statin-induced CRP reduction differed from the genetic determinants of statin-induced LDL reduction.
Introduction
The recent JUPITER trial demonstrated that potent statin therapy can cut by half the risk of future heart attack and stroke among men and women with low levels of lowdensity lipoprotein (LDL)-cholesterol who are at increased vascular risk due to elevated levels of C-reactive protein (CRP), a biomarker of inflammation. Further, in JUPITER, the absolute risk reduction attributable to statin therapy increased with increasing levels of baseline inflammation. However, whether directly targeting inflammation can reduce vascular risk remains uncertain and two large-scale placebo controlled trials-CANTOS and CIRT-have recently been initiated to address this issue. In this review, a discussion of clinical information linking inflammation to atherothrombosis is followed by an examination of the JUPITER trial, to dissect whether the benefits observed were due to LDL-C reduction alone, or to a combination of lipid lowering and inflammation inhibition. Finally, the core rationale and design features of the CANTOS and CIRT trials will be described.
Clinical Evidence Linking Inflammation and Atherothrombosis: From Basic Biology to JUPITER
Laboratory evidence has long indicated that inflammation plays crucial roles in all stages of the atherothrombotic process [1•] . Clinically, translation of the inflammatory hypothesis of atherosclerosis to practice has been based on observational evidence linking inflammatory biomarkers, such as high sensitivity C-reactive protein (hsCRP) [2, 3] , to the risk of future vascular events. As shown in recent meta-analysis, the magnitude of cardiovascular risk associated with a one standard deviation increase in hsCRP is at least as large as that associated with a one standard deviation increase in either total cholesterol or blood pressure [4••] . Further, the addition of hsCRP, along with family history, improves global risk prediction and is the basis for the commonly used Reynolds Risk Score [5] (www.reynoldsriskscore.com), which has recently shown superior discrimination and calibration when compared to the Framingham Risk Score in external validation [6•] .
To date, the use of hsCRP as a method to improve targeting of drug therapy has primarily come in the context of statin prescription. Following observations that statins reduce hsCRP in an LDL-independent manner, and that the magnitude of statin benefit is greater among those with inflammation [7, 8] , the observation was made in several trials that lower levels of hsCRP following statin therapy correspond to lower levels of risk [9] [10] [11] [12] 13 ••]. As such, statins were hypothesized to be "two-fers" that potently reduce LDL-C and have potentially relevant antiinflammatory effects. On that basis, the JUPITER trial was designed to address whether individuals who would never qualify for statin therapy due to already low levels of LDL-C might benefit from treatment if they had evidence of an enhanced inflammatory response, as determined by hsCRP>2 mg/L [14] .
In brief, in January of 2003, the JUPITER investigators began to enroll 17,802 men and women with no evidence of cardiovascular disease and normal to low levels of LDL cholesterol into a controversial trial testing whether individuals with an enhanced inflammatory response might benefit from aggressive statin therapy using a regimen of rosuvastatin 20 mg po daily. At study entry, the mean LDLC level for enrolled participants was just above 100 mg/dL, nearly half had Framingham scores of 10 % or less, and none were considered candidates for statin therapy under any current set of prevention guidelines. However, all trial participants had levels of the inflammatory biomarker hsCRP≥2 mg/L, putting them at elevated risk for future cardiovascular disease. Reflecting the investigators' interest in evaluating patient groups under-represented in prior statin trials, JUPI-TER enrolled 6,801 women, 5,695 participants age 70 or over, and more than 5,000 non-Caucasians.
As reported in 2008 [14] , random allocation to rosuvastatin 20 mg as compared to placebo within the JUPITER population resulted in a 54 % reduction in myocardial infarction (P00.0002), a 51 % reduction in ischemic stroke (P00.004), a 46 % reduction in need for bypass surgery or angioplasty (P<0.0001), and a 20 % reduction in all-cause mortality (P00.02). For the JUPITER primary endpoint of major arterial vascular events, the P-value for the overall 44 % relative risk reduction was <0.0000001. Effects were similar for women as for men, for the elderly, among those with and without metabolic syndrome, hypertension, or obesity, and in all ethnic groups [15, 16] . Overall, in this trial that targeted those with underlying evidence of inflammation, the Number Needed to Treat (NNT) for those with low levels of LDL-C but elevated hsCRP was smaller than the NNT for the treatment of dyslipidemia or high blood pressure in comparable primary prevention patients [17] . On the basis of these data, national guidelines in several countries have endorsed the use of statin therapy in primary prevention among those with elevated hsCRP [18] , and the United States Food and Drug Administration formally expanded the labeling of statin therapy to include those with elevated hsCRP and at least one additional risk factor, even if LDL-C levels are already low.
LDL-C Reduction, Inhibition of Inflammation, or Both?
Several additional analyses from JUPITER merit consideration as investigators try to understand whether the observed effects are due only to LDL-C reduction, or if they might also relate, at least in part, to anti-inflammatory effects.
First, on a prespecified basis, the JUPITER investigators also reported that rosuvastatin was associated with a 43 % reduction in venous thromboembolism (P00.007) [19] . This observation is relevant, since LDL-C is not a major determinant of venous thrombosis and there is no plaque in the veins to rupture. Yet, inflammation is highly relevant to in situ thrombosis, and thus the LDL-independent effects observed for rosuvastatin on clotting and thrombosis are consistent with the possibility of direct anti-inflammatory benefit, at least on the venous side of the circulation.
Second, as seen in the PROVE-IT, A to Z, REVERSAL, and ASCOT [13••] trials, those who achieved low levels of hsCRP while on rosuvastatin in JUPITER also achieved the greatest levels of risk reduction [20•] . Further, in JUPITER as in earlier studies, the magnitude of hsCRP reduction could not be predicted on the basis of the magnitude of LDL-C reduction.
Third, in gender stratified analyses, both the absolute risk of events in the placebo group and the absolute risk reduction associated with rosuvastatin was greater among those with higher levels of CRP at study entry, an effect not observed for LDL-C [21] .
Fourth, in a series of genetic analyses using genome wide association study, the genetic determinants of rosuvastatininduced LDLC reduction in JUPITER were found to differ from the genetic determinants of rosuvastatin-induced CRP reduction. Thus, separate and unrelated pathways appear to impact on statin-induced changes in lipids as compared to inflammatory mediators [22, 23] .
All of these findings are consistent with the hypothesis that part of the statin benefit observed in JUPITER was due to effects that go beyond simple reduction in LDL-C. However, because statins potently lower LDL-C, no statin trial can definitively address whether lowering inflammation per se will reduce vascular events. Yet, the clinical, laboratory, genetic, and pathologic data that derive from the statin literature provide the core basis for proceeding with a series of "cardiovascular inflammation reduction trials," designed to test directly whether specific anti-inflammatory agents without confounding effects on cholesterol can reduce cardiovascular events [24] .
Moving Beyond JUPITER Part I: CANTOS and Canakinumab
In the past year, our research group has initiated two hardendpoint clinical trials designed to address whether targeting inflammation directly will improve vascular outcomes.
The first trial, the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), is supported by Novartis and is evaluating a human monoclonal antibody that targets interleukin-1β (IL-1β) [25•] . Of inflammatory cytokines implicated in atherothrombosis, interleukin-1 plays an important role, as cholesterol crystals can activate the NLRP3 inflammasome, which results in cleavage of prointerleukin-1β into locally secreted IL-1β, in turn triggering a pro-inflammatory response [26••, 27] . IL-1β activates hepatic production of IL-6, which ultimately leads to increased production of inflammatory acute phase reactant biomarkers, including CRP. Intact mechanisms for macrophage autophagy also appear to play a role in regulating activation of the NLRP3 inflammasome by cholesterol crystals. In recent work, macrophage specific deletion of the essential autophagy gene ATG5 resulted in inflammasome activation and an increased burden of cholesterol crystals within atherosclerotic plaques [28] . These data raise the hypothesis that defective macrophage autophagy may result in unopposed cholesterol crystal-induced IL1-β release and subsequent promotion of atherogenesis.
Once activated, IL-1 can induce monocyte and leukocyte adhesion in human vascular endothelial cells [29, 30] . Reduced lesion formation has been reported in atherosclerosisprone mice deficient in either IL-1 or the type I IL-1 receptor, and studies performed on pig coronary arteries show increased neointimal formation with administration of IL-1 and reduced neointima formation in the presence of IL-1 receptor antagonism [31, 32] . Human studies supporting these concepts include observations that atherosclerotic coronary arteries have increased IL-1β levels; that IL-1Ra concentrations are higher among those with acute coronary syndromes; and that polymorphism in IL-1Ra associates with number of coronary lesions on angiography. Thus, inhibition of IL-1β has been hypothesized to have a beneficial effect on multiple pathways associated with atherosclerosis and its progression [30] .
CANTOS has been designed to directly address the hypothesis that IL-1β inhibition with canakinumab, a human monoclonal anti-human IL-1β antibody, might serve as a novel treatment to reduce cardiovascular event rates [25•] . Canakinumab directly binds human IL-1β and thus blocks the interaction of this cytokine with its receptors. In patients with type 2 diabetes, IL-1β antagonism with canakinumab produces a rapid and dose-dependent inhibition of the acute phase response resulting in sustained reductions in fibrinogen, IL-6, and CRP without impacting on lipid levels and with marginal effects on mediators of insulin resistance.
Formally, CANTOS is evaluating whether long-term treatment with canakinumab as compared to placebo will reduce rates of recurrent cardiovascular events among stable post-myocardial infarction patients who remain at elevated vascular risk due to persistently elevated levels of hsCRP (≥2 mg/l) despite usual care, including statin therapy. CANTOS will evaluate three active doses of canakinumab (50 mg, 150 mg, or 300 mg SC every three months) in comparison to placebo. The trial primary endpoint will be recurrent major cardiovascular events, defined as nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Secondary objectives of CANTOS include determination of the safety and efficacy of long-term canakinumab therapy and on other vascular events associated with inflammation. Further, among those with normal or impaired fasting glucose at the time of randomization, CANTOS will also address whether canakinumab will reduce the incidence of new onset diabetes.
CANTOS began enrollment in late 2011 and ultimately will include 17,200 adult men and women who have suffered a documented acute myocardial infarction at least 30 days before randomization, have completed any planned revascularization procedures associated with their initial infarction, and have evidence of systemic inflammation on the basis of an hsCRP≥2 mg/L, despite the stable use of standard secondary prevention therapies. As canakinumab is an inhibitor of innate immunity, patients with a suspected or known immunocompromised state; those taking another biologic agent that targets the immune system (TNF blockers, anakinra, rituximab, abatacept, tocilizumab); those already taking methotrexate at a dose exceeding 15 mg weekly; and those with a history of or at high risk for tuberculosis or HIV related disease will not be eligible.
Moving Beyond JUPITER Part II: CIRT and Low-Dose Methotrexate
The second trial we have initiated is the National Heart, Lung, and Blood Institute (NHLBI)-sponsored Cardiovascular Inflammation Reduction Trial (CIRT), which is evaluating the role of low-dose methotrexate as a potential anti-inflammatory agent to suppress cardiovascular event rates [24] .
Low-dose methotrexate (target dose range 15-20 mg per week) is commonly used as the treatment of choice for rheumatoid arthritis and psoriasis, patient groups known to have elevated risks for cardiovascular disease. As methotrexate is a generic agent with nearly 40 years of clinical experience, guidelines from the American College of Rheumatology provide clear data regarding dosing regimens, drug monitoring, and the identification of high-risk patient subgroups [33] . While low-dose methotrexate reduces inflammatory biomarkers including CRP and IL-6 in patients with rheumatoid arthritis, low-dose methotrexate does not have any major effects on lipid levels. As such, like canakinumab, low-dose methotrexate provides a therapeutic method to test the inflammatory hypothesis of atherothrombosis without confounding effects on plasma lipid levels.
The CIRT is based both on available observational evidence that those taking the drug have lower vascular event rates, and on experimental data suggesting that methotrexate reduces vascular lesion formation in animal models.
With regard to observational evidence, a series of case control and prospective cohorts of patients with rheumatoid arthritis and psoriatic arthritis have found that those given low dose methorexate have reduced rates of myocardial infarction and vascular death, even though those receiving low-dose methotrexate often had worse vascular risk factor profiles [34] . In a recent meta-analysis of these studies, lowdose methotrexate was associated with a 21 % lower risk for total cardiovascular disease and an 18 % lower risk of myocardial infarction, with only modest evidence of between-study heterogeneity [35•] . Other observational studies of rheumatoid arthritis patients taking low-dose methotrexate have shown improvement in heart failure and reduction in carotid intima media thickness [36] . The observation that acute myocardial infarction mortality has declined as anti-inflammatory therapy has become more widespread for rheumatoid arthritis is consistent with these data [37] .
With regard to experimental data, mechanistic studies suggest that atheroprotective effects of low-dose methotrexate may accrue in part from enhanced release of adenosine and a consequent facilitation of cholesterol efflux and reverse cholesterol transport from arterial wall foam cells via upregulated expression of cholesterol 27-hydroxylase (HY27) and the ATP-binding cassette transporter (ABCA1) [38, 39] . Low-dose methotrexate also appears to have effects on apoptosis and on the suppression of adhesion molecule function. Recently, Bulgarelli and colleagues have shown that methotrexate inhibits atherogenesis in cholesterol fed rabbits [40] ; specifically, in New Zealand rabbits fed a 1 % cholesterol diet for 60 days, metotrexate reduced lesion areas by 75 % and reduced the intima-media ratio two-fold. In these studies, methotrexate also inhibited macrophage migration to the intima and markedly reduced apoptotic cell accumulation and migration. All of these effects are consistent with anti-atherosclerotic actions for low-dose methotrexate.
CIRT will formally test whether low-dose methotrexate can reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome, conditions associated with an enhanced proinflammatory response. CIRT is a randomized, double blind, placebo-controlled, multicenter, event-driven trial that will enroll 7,000 men and women from the United States and Canada. Following a 5-week open-label run-in, eligible participants who have suffered documented myocardial infarction in the past 5 years will be randomly allocated to usual care plus placebo or usual care plus low-dose methotrexate (initial target dose 15 mg po per week with a safetybased titration to 20 mg po per week after 4 months based on evidence of safety and tolerability). All study participants will additionally receive 1 mg daily oral folate. Low-dose methotrexate complications will be minimized through education programs for all investigators and coordinators, through enhanced communication with study participants; by limiting enrollment to those with no evidence of malignancy, hepatitis, renal dysfunction, chronic infection, or other methotrexate risk factors; and through regular monitoring of liver function and hematologic indices using a centralized methodology.
The primary trial endpoint of CIRT is the rate of recurrent myocardial infarction, stroke, or cardiovascular death. As in CANTOS, secondary endpoints include all-cause mortality, additional vascular disorder associated with a proinflammatory state, and incident diabetes among those with metabolic syndrome at study entry. This latter issue is based on evidence indicating a major role for inflammation in diabetes [41••] .
Conclusion
Taken together, CANTOS and CIRT provide the clinical community with two "swings of the bat" to address whether reducing inflammation can reduce vascular event rates. Each trial employs an event-driven protocol to address whether a broad spectrum anti-inflammatory (low-dose methotrexate) or a targeted vascular anti-inflammatory (cankinumab) as compared to placebo can reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among stable coronary artery disease patients who remain at risk due to a persistent pro-inflammatory response.
Sites in the United States or Canada interested in participating in CANTOS or CIRT can get further information at theCANTOS.org and theCIRT.org websites, or by calling (855) 437-9330. Information on both trials is also available at ClinTrials.gov.
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